-->

Aug 16, 2016

Why Russia Is an Attractive Market for Clinical Trials

Russia is an emerging 
market for clinical trials.

by Sue Lee

Technical Portfolio Manager

World Courier Management


When you think of countries as candidates for clinical trials, which ones come to mind?  North America, Great Britain, France?

What about Russia?


Russia is the largest country in the world.  Today’s Russian clinical trial market is worth 880 million dollars and there is every expectation that it will continue to grow. The only question is, at what rate? If growth remains, then, at the current rate of 4.65 per cent per year to 2020, then there will be approximately 1086 new studies compared to a total of 790 in 2013. 



This article is related to the White Paper: 
FDA Inspections of Clinical Investigators: Are You Ready?
To get the full details, please download your free white paper.


For a fascinating overview of the clinical trial opportunities in this emerging market, read the complete article in Outsourced Pharma.


Sue Lee has worked for World Courier for more than 25 years. During that time, she has experienced a variety of customer service and operational functions, including the setting up of numerous, multinational, clinical studies. She has orchestrated the shipping thousands of shipments with very specific temperature requirements to a host of challenging locations, and each presenting their own obstacles and dilemmas. 





Watch Related Videos:

Gaining a Competitive Advantage with MasterControl
An Executive Perspective of MasterControl
Download Free Resources
White Paper: ICH Q10 - Pharmaceutical Quality Systems - 'An Opportunity for Us All'
White Paper: Six Corporate Oversights of Quality and Compliance Issues in Pharmaceutical Environments
White Paper: The Pharmaceutical Industry's Transition to Electronic Processes
Q&A: New ICH Q10 Harmonization Guidance for the Pharmaceutical Industry
Promotional: MasterControl Pharmaceutical & Biotechnology Solutions